⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2024HeliyonOpen Access

Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory/relapsed AML: case report and exploration of possible mechanisms

Man Li Xiawan Yang Yaonan Hong Qi Liu Yingying Shen Tonglin Hu Yiping Shen Guoyin Kai Dijiong Wu

View Full Paper

Ask AI

Bookmark

Share

Abstract

Venetoclax, a selective BCL-2 inhibitor, has shown superior efficacy in the treatment of AML. Nevertheless, some AML patients with

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Li et al. (2024) studied this question.

synapsesocial.com/papers/68e5e1d7b6db643587576646 https://doi.org/10.1016/j.heliyon.2024.e35847

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Gilteritinib with or without venetoclax for relapsed/refractory <i>FLT3</i>‐mutated acute myeloid leukaemia2024 · 5 citations
2Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia.2025 · 8 citations
3Real‐world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS‐like tyrosine kinase 3 ( <scp>FLT3</scp> )‐mutated relapsed/refractory acute myeloid leukaemia: A <scp>UK</scp> single‐centre experienceOriginal Research · 2026
4Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AMLEarly-Phase Clinical Trial · 2026 · 3 citations
5Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3-Mutated AML PatientsEarly-Phase Clinical Trial · 2023 · 26 citations

Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy2026
Negative feedback regulation of nfkb, MAPK, and JAK-STAT drives adaptive resistance to gilteritinib in AML2025
Efficacy of the triplet therapy with venetoclax, azacitidine and gilteritinib for the treatment of FLT3-ITD mutated AML patients with refractory/relapsed disease or persistent minimal residual disease bridging to allogeneic hematopoietic stem cell transplantation2025
A comparative analysis of women entrepreneurs’ challenges in Male- and Female-dominated Industries: Evidence from IranHeliyon · 2026
Knowledge and perception of producers and consumers on the production process, perceived health benefits, and sensory properties of “mendím me zoñ”, a traditional Cameroonian herbal teaHeliyon · 2026

More from Heliyon

More from Zhejiang Chinese Medical University

More from Wenzhou Hospital of Traditional Chinese Medicine